 |
Biosketch
July 9, 2007
STEPHAN R. TARGAN, M.D.
CURRICULUM VITAE
PERSONAL HISTORY:
Business Address: Division of Gastroenterology
Cedars-Sinai Inflammatory Bowel Disease Center
Cedars-Sinai Medical Center
Suite D4063
8700 Beverly Blvd.
Los Angeles, California 90048
(310) 423-7724 phone
(310) 423 0224 fax
targans@cshs.org
Citizenship: United States
Education: B.A. Johns Hopkins University, Baltimore, Maryland-1967
M.D. Johns Hopkins University, Baltimore, Maryland-1971
Medical Internship: Harbor-UCLA Medical Center, Torrance California 1971-1972
Medical Residence: Harbor-UCLA Medical Center, Torrance, California 1972-1974
Medical Fellowships: Division of Infectious Diseases, Harbor-UCLA Medical Center,
Torrance, California 1974-1976
Division of Gastroenterology, UCLA School of Medicine, Los Angeles,
California 1976-1978
Licensure: California Physicians and Surgeons, July 1972, No. G22752
Board Certification: American Board of Internal Medicine, June 30, 1974
American Board of Internal Medicine, Subspecialties:
Infectious Disease, October 16, 1976
Gastroenterology, October 16, 1979
PROFESSIONAL EXPERIENCE:
Present Positions:
1986 - present Professor of Medicine (Gastroenterology), UCLA School of Medicine, Los
Angeles, California
1992 - present Director, Cedars-Sinai Medical Center-Inflammatory Bowel Disease Center
1992 - present Feintech Family Chair in Inflammatory Bowel Disease
1996 - present Director, Cedars-Sinai Medical Center-Division of Gastroenterology
1999 - present Associate Chairman of Medicine for Academics and Research, Cedars-Sinai
Medical Center
2002 - present Director, Immunobiology Research Institute
Targan, Stephan R.
July 9, 2007
Page 2
Previous Positions:
1964-1966 Research Associate, Harbor-UCLA Medical Center, Torrance, California.
* In Residence
1967-1969 Research Associate, UCLA Division of Gastroenterology.
1977-1978 NIH Post-Doctoral Scholar, UCLA Department of Microbiology and
Immunology.
1978-1980 Research Associate, Wadsworth VA Hospital, Los Angeles, California.
1978-1981 Assistant Professor of Medicine* UCLA School of Medicine, Los Angeles, CA.
1980-1985 Clinical Investigator, Wadsworth VA Hospital, Los Angeles, California.
1981-1986 Associate Professor of Medicine* UCLA School of Medicine, Los Angeles, CA.
1985-1991 Director, Immunology Core, Center for the Study of Inflammatory Bowel Disease
1985-1991 Associate Director, NIH, Center for the Study of Inflammatory Bowel Disease
1985-1992 Director, Inflammatory Bowel Disease Center, UCLA School of Medicine
PROFESSIONAL ACTIVITIES:
Committee Service:
1985-1994 Crohn's and Colitis Foundation of America Grants Review Committee
1987 Organization Committee and Moderator, International Symposium on Inflammatory
Bowel Disease
1987-1988 Acting Chairman, Crohn's and Colitis Foundation of America Grants Review
Committee
1987-1989 Program Planning Committee, Clinical Immunology Society
1988 NIH Ad Hoc Member, Experimental Therapeutic Immunology Study Section
1989-1993 Chairman, Crohn's and Colitis Foundation of America National Scientific Advisory
Committee
1990-1994 Steering Committee, American Gastroenterological Association, Gastroenterology
Research Group - Inflammatory Bowel Disease/Mucosal Immunology
Representative
1992-1996 NIH National Institutes of Allergy and Immunologic Diseases Study Section
1998-2004 NIH National Institutes of Diabetes, Digestive and Kidney Diseases, General
Medicine-A2 Study Section
1999-2003 Chairman, Research Initiatives Committee, Crohn’s and Colitis Foundation of
America, National Scientific Advisory Committee.
2000-2001 AGA Nominating Committee
2002-2004 Chairman, NIDDK GMA-2 Study Section
2002-2004 Counselor for the Inflammatory Bowel Disease Section of the AGA - IBD Section
2006-Present AGA Fellow, Governing Board of the American Gastroenterological Association
Professional Associations:
1971 Diplomate, National Board of Medical Examiners
1976 - California Medical Association
1976 - American Society for Microbiology
1979 - American Gastroenterological Association
1979 - Society for Experimental Biology and Medicine
1979 - Fellow, American College of Physicians
1981 - American Federation for Clinical Research
1981 - Los Angeles Society of Internal Medicine
1981 - American Association of Immunologists
1985 - American Society for Clinical Investigation
1986 - Western Society for Clinical Investigation
Targan, Stephan R.
July 9, 2007
Page 3
1987 - Western Association of Physicians
1990 - Clinical Immunology Society
1990 - Mucosal Immunology Society
1998 - American Association of Physicians
Editorial Service:
1986 - 1990 Associate Editor, The Journal of Immunology
1989 - 1990 Editor-in-chief, Autoimmunity Forum - Gastroenterology Section
1989 - 1991 Editorial Board, Clinical Immunology Reviews
1994 - Associate Editor, Inflammatory Bowel Diseases
2004 – present Editorial Board, The Canadian Journal of Gastroenterology
2004 – present Editorial Board, Clinical Gastroenterology and Hepatology
Consulting Activities:
1995 - 1998 Scientific Advisory Board, GeneNetworks, Inc.
1996 - Founder and Board of Directors, Prometheus Laboratories, Inc.
1996 - Annenberg Center for Health Sciences/Medical Education/IBD Mentoring
1997 - 1999 Point Counterpoint Series in Medical Education
1998 - 2001 Founder and Board of Directors, Santarus, Inc.
1998 - Scientific Advisory Board, Seaver Foundation
1999 - 2003 Founder and Trustee, National Inter-laboratory Collaboration (N.I.C.E.)
Foundation
2001 - Chairman, Scientific Advisory Board, Santarus Corporation
HONORS AND SPECIAL AWARDS:
Phi Beta Kappa, Junior Year, 1966
Norman Jellife Clinical Nutrition Scholarship, 1968
Research Associates' Award, Wadsworth VA Hospital, 1978
Clinical Investigator Award, Wadsworth VA Hospital, 1980
Crohn's & Colitis Foundation of America 25th Anniversary Scientific Leadership Award 1992
American College of Physicians. “The Year’s Most Important Papers in Internal Medicine
Subspecialties 1998.” Greenberger NJ. (Targan, et al. NEJM 1997;33:1029-35.)
RESEARCH GRANTS
Basic Science (awarded since 1990):
1990-1992 Crohn’s and Colitis Foundation of America
A Diagnostic Marker for Ulcerative Colitis
Principal Investigator. $80,000/year direct costs.
1992-1994 Crohn’s and Colitis Foundation of America
Role of Activated T-cells in Gut Mucosa
Principal Investigator. $80,000/year direct costs.
1991-1995 NIH RO1 DK43026
IBD: Role of Antineutrophil Cytoplasmic Antibodies –
Principal Investigator. $120,000/year direct costs.
1993-1997 NIH PO1 AI34567
Project 4, Effects of Superantigens on IBD Mucosal T-cells
Project Principal Investigator.$68,000/year direct costs.
1994-1996 Crohn’s and Colitis Foundation of America
Targan, Stephan R.
July 9, 2007
Page 4
Role of Antineutrophil Cytoplasmic Antibodies
Principal Investigator. $80,000/year direct costs.
1996-1998 Crohn’s and Colitis Foundation of America.
Role of Tumor Necrosis Factor in Crohn’s Disease Pathogenesis
Principal Investigator. $80,000/year direct costs.
1992-2006 NIH RO1 DK43211
IBD: Mucosa Specific Regulation of IFN- γ Production
Principal Investigator. $200,000/year direct costs.
1995-2005 NIH PO1 DK46763
IBD: Genetic and Immunopathologic Mechanisms
Principal Investigator/Program Project Director. $871,000/year direct costs.
1995-2005 NIH PO1 DK46763
IBD: Genetic and Immunopathologic Mechanisms: Administration Core -
Principal Investigator/Core Director. 55,000/year direct costs.
1995-2005 NIH PO1 DK46763
IBD: Genetic and Immunopathologic Mechanisms: Tissue Procurement Core -
Principal Investigator/Core Director. $112,000/year direct costs.
1995-2005 NIH PO1 DK46763
IBD: Genetic and Immunopathologic Mechanisms: Project 2 - Ulcerative
Colitis Specific pANCA: Role in Disease Pathogenesis.
Project Principal Investigator. $124,000/year direct costs.
1999-2009 NIH RO1 DK56328
IBD: TNF- α and Crohn's Disease Mucosal Inflammation.
Principal Investigator. $250,000/year direct costs.
NIH
2004-2009 CTLA4 Inhibition and Autoimmunity in Melanoma (Weber, USC, PI)
Subcontract Investigator. $75,000/year direct costs
2005-2007 CCFA
The Flagellin, Anti-CBir1, Defines a Subtype of Crohn’s Disease
Principal Investigator. $100,000/year direct costs.
2005-2010 NIH
Innate and adaptive microbial immunity in IBD (C. Elson, UAB, PI)
Project 4: Flagellin as a Marker for a Subtype of Crohn’s Disease
Project Principal Investigator. $126,853/year direct costs.
2005-2010 NIH PO1 DK46763
IBD: Genetic and Immunopathologic Mechanisms
Principal Investigator/Program Project Director. $1,047,653/year direct costs.
IBD: Genetic and Immunopathologic Mechanisms: Administration Core -
Principal Investigator/Core Director. 54,656/year direct costs.
IBD: Genetic and Immunopathologic Mechanisms: Tissue Procurement Core -
Principal Investigator/Core Director. $148,714/year direct costs.
NIH PO1 DK46763
IBD: Genetic and Immunopathologic Mechanisms: Project 2 -
Immunopathologic mechanisms leading to an aggressive Crohn’s disease
immuno-phenotype.
Project Principal Investigator. $141,379/year direct costs.
2006-2014 NIH R37 DK43211(MERIT)
IBD: Mucosa Specific Regulation of IFN- γ Production
Principal Investigator. $250,000/year direct costs
Clinical Research (selected):
Targan, Stephan R.
July 9, 2007
Page 5
1993-1994 Merck, Sharp and Dohme Research Inst. #019-004
MK-0591 Multiple Dose Tolerability Study in Patients with Ulcerative Colitis.
Principal Investigator.
1994-1995 Immunex - Protocol No. 16.0005
Multicenter Phase I/II Trial of Recombinant Human TNF Receptor (rhu
TNFR:Fc) in active Crohn’s Disease.
Principal Investigator.
1994-1995 Centocor - Study No. C0168T11
Phase II Multi-Center Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in
the Treatment of Patients with Active Crohn’s Disease.
Principal Investigator.
1994-1995 Centocor - Study No. C0168T12
Phase II Multi-Center Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in
the Treatment of Patients with Ulcerative Colitis.
Principal Investigator.
1995-1996 Centocor - Protocol No. C0168T16
A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled,
Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in
the Treatment of Patients with Active Crohn’s Disease.
PI: Principal Investigator.
1995-1996 Schering-Plough - Study No. C95-038
Safety, Tolerance and Activity of Multiple Doses of Subcutaneous rhuIL-10 (SCH
52000) in Patients with Mildly to Moderately Active Crohn’s Disease –Phase
II/III.
Principal Investigator.
1995-1996 Schering-Plough - Study No. C95-039
Safety, Tolerance and Activity of Multiple Doses of Subcutaneous rhuIL-10 (SCH
52000) in Patients with Mildly to Moderately Active Ulcerative Colitis (Phase
I/II)
Principal Investigator.
1996-1997 Schering-Plough - Study No. C/I95-152
Safety, Tolerance and Efficacy of Multiple Doses of Subcutaneous rhuIL-10 (SCH
52000) in Patients with Chronic Active Crohn’s Disease.
Principal Investigator.
1996-1997 Schering-Plough - Study No. C/I95-171
Companion Protocol to C/I95-152: Safety and Tolerance of Re-treatment with
Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patient’s with Chronic
Active Crohn’s Disease.
Principal Investigator.
1996-1997 Centocor
A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal
Antibody (cA2) in the Treatment of Patients with Enterocutaneuos Fistulae as a
Complication of Crohn’s Disease .
Principal Investigator.
1997 Glaxo Wellcome - Protocol No. IM1A4001
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of
Intravenous Azathioprine Loading to Decrease the Time to Response in Subjects
with Steroid-Refractory Crohn’s Disease.
PI: Principal Investigator.
Targan, Stephan R.
July 9, 2007
Page 6
1998-1999 Tap Holdings, Inc. - Protocol No. M97-713
A Phase II Study of the Safety and Efficacy of TAK-603/A-165646 in Patients with
Crohn’s Disease.
Principal Investigator.
1998-1999 Celltech Therapeutics Limited - Protocol No. CDP571-009
A Phase II, Multi-National, Double-Blind, Placebo-Controlled, Parallel Group
Study to Assess the Safety and Potential of the Engineered Human Anti-TNF α
Antibody, CDP571, to Treat Patients with Moderate to Severe Crohn's Disease
Following an Intravenous Dose of 20 or 10mg/kg of CDP571 Followed by 8- or
12- Weekly Dosing with 10mg/kg CDP571 over 24 Weeks.
Principal Investigator.
1998-1999 Celltech Therapeutics Limited - Protocol No. CDP571-010
A Phase II, Multi-National, Double-Blind, Placebo-Controlled, Parallel Group,
16 Week Study to Assess the Safety and Potential of the Engineered Human Anti-
TNF α Antibody, CDP571, to Prevent Disease Flare Whilst Allowing Steroid
Withdrawal in Steroid-Dependent Patients with Crohn's Disease Following an
Intravenous Dose of 20mg/kg and then, 8 Weeks Later, 10mg/kg of CDP571.
Principal Investigator.
1998-1999 Centocor - Protocol No. C0168T24
Extended Treatment with Anti-TNF Chimeric Antibody (infliximab) for Treatment
of Patients with Active Crohn’s Disease Previously Enrolled in Centocor
Protocols [C0168T08, C0168T11, C0168T16, C0168T20].
Principal Investigator.
1999-2001 Centocor
A Randomized Double-Blind, Placebo-Controlled Trial of Anti-TNF Chimeric
Monoclonal Antibody (Infliximab, Remicade) in the Long-Term Treatment of
Patients with Moderately to Severely Active Crohn’s Disease (ACCENT I).
Principal Investigator.
2001-2002 IDEC Pharmaceuticals-Protocol 131-60
A Phase II, Randomized, Placebo-Controlled, Multiple-Dose, Safety, Clinical
Activity and Dose-Finding Study of IDEC-131 (monoclonal antibody against
CD154) in Patients with Active Crohn’s Disease.
Principal Investigator.
2003 Abbott Laboratories
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of The
Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical
Remission in Subjects with Crohn's Disease.
Principal Investigator
2003 Abbott Laboratories
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the
Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of
Clinical Remission in Subjects with Crohn’s Disease.
Principal Investigator.
2003-2004 Protein Design Laboratories
Double-Blind, Placebo-Controlled, Study to Determine the Safety and Efficacy of
a Humanized Anti-Interferon-y Monoclonal Antibody (HuZAF) Administered to
Patients with Moderate to Severe Crohn’s Disease.
Principal Investigator.
2003 Protein Design Laboratories
A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe
Ulcerative Colitis That is Refractory to Corticosteroids.
Principal Investigator.
Targan, Stephan R.
July 9, 2007
Page 7
2003-2004 Protein Design Laboratories
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Dose-
Ranging Study of Intravenous Daclizumab in Patients with Moderate-to Severe
Ulcerative Colitis.
Principal Investigator.
2003-2004 Elan Pharmaceuticals
Phase III, International, Multicenter, Double-Blind, Placebo-Controlled Study of
the Safety, Efficacy, and Tolerability of Intravenous AntegrenTM (natalizumab) in
Subjects with Moderately to Severely Active Crohn’s Disease.
Principal Investigator.
2005 Chemocentryx
A Pilot, Double-Blind, Placebo-Controlled, Parallel Group, Two Stratum Study of
the Safety, Tolerability, Immunologic and Clinical Activity, and Population
Pharmacokinetics of CCX282-B Administered for Four Weeks in Patients with
Moderate to Severe Crohn's Disease.
Principal Investigator.
2005 Medarex
A Phase I, Blinded, Multicenter, Dose-escalation, Placebo-controlled, Singledose
Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in
Patients with Active Ulcerative Colitis.
Principal Investigator.
2005 Genentech
A Phase I, Multicenter, Randomized, Placebo-Controlled, Blinded Study of
Rituximab in Subjects with Active Ulcerative Colitis.
Principal Investigator.
2005 Protein Design Laboratories
A Phase 1, Dose-Escalation, Pilot Study of Visilizumab in Patients with Severe
Ulcerative Colitis That is Refractory to Corticosteroids.
Principal Investigator.
LECTURES AND PRESENTATIONS 2002 - 2007
Grand Rounds: “IBD 2002: Translational Medicine – Fast Tracking Basic Science Discovery.”
February 20, 2002, Connecticut State Medical Society/GI Division, New Haven, Connecticut.
Samuel D. Kushlan Lecture: “Cutting Edge Diagnostics & Therapeutics in IBD.” February 21,
2002, Yale University, New Haven, Connecticut.
Grand Rounds and Conference: “IBD 2002: Translational Medicine – Fast Tracking Basic
Science Discovery.” University of Medicine & Dentistry of New Jersey, Robert Wood Johnson
Medical School, New Brunswick, New Jersey.
2nd Annual Workshop on Immunogenetic of Intestinal Inflammation: Role of Genetics and
Functional Genomics. March 22-23, 2002, University of Virginia, Charlottesville, Virginia.
Faculty Member – 7th Annual Young Investigators Conference in Digestive Diseases. April
11-14, 2002, Indian Wells, California.
Targan, Stephan R.
July 9, 2007
Page 8
Crohn’s & Colitis Foundation of America: “Challenges in IBD Research: Updating the Scientific
Agendas.” May 2-5, 2002, Phoenix, Arizona.
DDW CME Symposium: “New Directions in the Theory and Management of Inflammatory
Bowel Disease.” May 18, 2002, San Francisco, California.
DDW Satellite Symposium: “FAQs & Fictions in Managing IBD.” May 20, 2002,
San Francisco, California.
DDW CME Symposium: “Targeting Inflammatory Bowel Disease (IBD): The Role of Emerging
Biologic Therapies.” May 21, 2002, San Francisco, California.
Post DDW Conference: “Controversies in Inflammatory Bowel Disease: Update in IBD.”
July 12-14, 2002, Keck School of Medicine, University of Southern California, Los Angeles,
California.
CCFA Crohn’s & Colitis at the Crossroads: “Biologic Therapies for Crohn’s & Colitis.”
September 27-28, 2002, Mohegan Sun Resort, Uncasville, Connecticut.
TNF Superfamily Conference 2002: “Modulation of TNF and TNF-like molecules: Implications
for disease modifications.” October 30 – November 2, 2002, San Diego, California.
Symposium on Gastroenterology: “Novel Therapies for Inflammatory Bowel Disease: who,
when and how?” February 7, 2003, Royal College of Physicians of Edinburgh, Scotland.
Gastroenterology Conference: “Novel Therapies in Inflammatory Bowel Disease – Anti-TNF
Therapies and Beyond.” February 13, 2003, Cedars-Sinai Medical Center, Los Angeles,
California.
Shapiro Lecture: “Mucosal Specific Mechanisms of IFN-γ Regulation” March 5, 2003,
University of Pennsylvania.
International Meeting on IBD: “Understanding Therapy: Immunosuppressives” April 15, 2003,
Capri, Italy.
DDW/AGA – Meet-the-Professor-Luncheon: “TNF-Biology and Therapeutic Target” May 20,
2003, Orlando, Florida.
DDW CME Symposium: “Targeting Inflammatory Bowel Disease: Selective Inhibition of the α4
Integrin Adhesion Molecule” May 20, 2003, Orlando, Florida.
Gastroenterology Fellowship Conference: “Anti TNF Treatment of IBD Good, Bad, and Future”
May 30, 2003, University of California Los Angeles, Los Angeles, California.
Crete 2003 International Symposium: “The Role of T-Lymphocytes in Gut Inflammation:
Animal Models vs. Human Disease.” June 27, 2003, Crete, Greece.
IBD Retreat: “Integrating Murine and Human Science in IBD: The “Road Map” to Future
Discovery.” July 15, 2003, University of Chicago, Illinois.
Medical Education Program: “Update in the Management of GI Disorders: Focus on GERD and
IBD.” July 29, 2003, Westlake Village, California.
Targan, Stephan R.
July 9, 2007
Page 9
Cedars-Sinai Medical Center – GI Symposium: “The Biologic Attack of Crohn’s Disease” and
“Predicting Outcomes of Therapy in Steroid-Refractory Ulcerative Colitis.” September 12,
2003, Napa Valley, California.
GI Grand Rounds at the Brigham and Women’s Hospital – “Serologic Responses in IBD:
Genomics, Phenomics and Pathogenetic Paradigms.” January 26, 2004, Boston Massachusetts.
Inflammatory Bowel Diseases 2004 Conference – “Mucosal Immunity in Ulcerative Colitis.”
February 5, 2004, Amsterdam, The Netherlands.
Gastroenterology and Hepatology 2004 – “Serologic Testing in IBD – Can the Lab Help Us?”
February 28, 2004, UCLA School of Medicine, Los Angeles, California.
Second Annual Inflammatory Bowel Disease Symposium – “Pharmacogenetics & Metabolite
Levels of Azathioprine/6MP in IBD.” March 13, 2004, Seattle, Washington.
International Organization of Inflammatory Bowel Disease (IOIBD) – “The Future of IBD
Therapy: From Monoclonal Antibodies to Gene Therapy.” March 18, 2004, University of
California in San Francisco.
Digestive Disease Week (DDW) – “Challenges in Crohn’s Disease: The Role for Current and
Future TNF Antagonists.” May 17, 2004, New Orleans, Louisiana.
Digestive Disease Week (DDW) – Satellite Symposium, “Controversies in IBD.” May 17, 2004,
New Orleans, Louisiana.
Digestive Disease Week (DDW) – “ Clinical Updates on the use of Alpha 4 Integrin Antagonists
for Targeting Crohn’s Disease.” May 18, 2004, New Orleans, Louisiana.
Lecture Tour in Australia – “IBD: Inflammatory Bowel Disease 2004 - From Bench to Bedside.”
(5) Lectures: Sydney, Brisbane, Melbourne, Perth, and Adelaide. July 20th to July 28th 2004.
AGA-BSG Research Meeting: Pathogenesis of Intestinal Inflammation - “Translational to
Therapy.” Oxford, UK. September 2-3, 2004.
American Physiological Society (APS) Translational Research Conference 2004, Immunological
and Pathophysiological Mechanisms in Inflammatory Bowel Disease. “Anti-Cytokine Therapy in
the Treatment of IBD.” Snowmass, Colorado. September 8-11, 2004.
The 29th Annual Meeting of the Texas Society for Gastroenterology and Endoscopy and
American College of Gastroenterology (ACG) Regional Course. “The Future of IBD” and
“Immunomodulatory Therapy for IBD: Present and Next Generation.” (2) Lectures. Dallas,
Texas. September 17-18, 2004.
Cedars-Sinai Medical Center - Annual Update in Gastroenterology Symposium. “Understanding
Pathophysiology for Design of Novel Diagnostics & Therapeutics.” Monterey, California.
October 15-17, 2004.
Visiting Professor at University of Michigan - “Unique Regulation of Mucosal Interferon
Gamma by TNF-like molecules.” Ann Arbor, MI. November 7, 2004.
Targan, Stephan R.
July 9, 2007
Page 10
AGA IBD 2005 Symposium: Interactive Updates with the Experts - “Pathogenesis of IBD.” San
Diego, CA . January 28, 2005
Presentation at the Treatment of IBD In The Era of Biologics Symposium - “Current status of
anti-TNF antibody treatments in Crohn’s disease” and “New biological therapies: which one and
do we need them?”. February 11, 2005, Leuven, Belgium.
CCFA IBD Clinical Trials Course: Principles and Practice - “Pathogenesis of IBD” & The future
of IBD”. St. Petersburg, Florida. March 11, 2005.
Grand Rounds USC - “Pathophysiology of IBD”. Los Angeles, CA. March 25,2005.
Presentation at Curatio CME Symposium during Digestive Disease Week (DDW)
“Treatment of Ulcerative Colitis: The Emerging Role of Biologics”. May 17, 2005, Chicago,
Illinois.
GI Grand Rounds at the New York Presbyterian Hospital - “Immune Markers for Inflammatory
Bowel Disease”. June 14, 2005, New York, New York.
Lecture at Immune Tolerance Network Steering Committee Meeting - “Autoantigens in
Inflammatory Bowel Disease”. June 23, 2005, Washington, D.C.
Presentation at Human Genome Sciences - “Unique Regulation of Mucosal IFN-γ by TNF-like
molecules”. June 24, 2005, Washington, D.C.
Presentation at 12th International Congress of Mucosal Immunology - “Novel TNF-Super
Family Members Involved in Mucosal Inflammation”. June 28, 2005, Boston Massachusetts.
Presentation at 2005 Post-Digestive Diseases Week Meeting - “Controversies in IBD”. July 17,
2005, La Costa, CA.
IBD International Symposium - “Current Limitations of IBD treatment: Keynote Lecture -
Where do we go from here?” September 2-3, 2005, Münster, Germany.
The World Congress of Gastroenterology 2005 -“Anti-TNF - First Line Therapy”.
September 10-14, 2005, Montréal, Canada.
The World Congress of Gastroenterology 2005 -“Immune Mechanisms: What to Block, What to
Stimulate”. September 10-14, 2005, Montréal, Canada.
Department of Medicine Grand Rounds UCLA - “The Changing Faces of the Inflammatory
Bowel Disease in 2005”. Los Angeles, CA. September 28, 2005.
Cedars-Sinai Medical Center - Annual Update in Gastroenterology Symposium. “Reclassifying
Ulcerative Colitis & Crohn’s Disease.” La Jolla, CA. October 21-23, 2005.
Cedars-Sinai Medical Center - Rheumatology Grand Rounds. “ The Changing Faces of the
Inflammatory Bowel Diseases in 2005.” Los Angeles, CA. October 26, 2005.
ACG Satellite Symposium - “Severe Ulcerative Colitis.” Honolulu, HI. October 31, 2005.
Targan, Stephan R.
July 9, 2007
Page 11
Massachusetts General Hospital - Center for the Study of IBD 15th Annual Symposium - “The
Role for LIGHT and TL1A in Th1 Mediated Mucosal Inflammation.” Boston, MA. November
10, 2005.
22nd Annual Postgraduate Medicine Course- Update in Gastroenterology, Hepatology &
Nutrition, Columbia University & Weill Medical College of Cornell University. “Deconstructing
the Dysregulated Immune Response in IBD: Past, Present and Future.” New York, NY.
December 2-3, 2005.
Gilead Science, Inc. - “Pathogenesis of IBD 2006: Implications for Present and Future
Treatments.” San Francisco, CA . February 10, 2006.
CCFA Microbial-Host Interactions Workshop - “Serologic Responses in IBD Patients to Defined
Antigens.” St. Petersburg, FL. March 16-19, 2006.
P&GP Satellite Symposium: Interrogate the Innovators British Society Gastroenterology Annual
Meeting - “Innovative Treatment Approaches to GI Diseases: A novel Paradigm for IBD.”
Birmingham, UK. March 21, 2006.
4th International Meeting on Inflammatory Bowel Diseases: On The Way To New Therapies -
“Breaking News: A Paradigm for Merging Clinical and Basic Science.” Capri, Italy. April 9-12,
2006.
AGA CME Clinical Symposium during Digestive Disease Week (DDW). Anti-Adhesion
Molecules and Other Strategies for Crohn’s Disease. Los Angeles, CA. May 20-25 , 2006
AGA Spring Postgraduate Course at DDW 2006 - “Serological Testing for Celiac Sprue and
IBD: Risks of Mis-Diagnosis and Missed Diagnosis.” Los Angeles, CA. May 20, 2006.
Falk Symposium 154, Inflammatory Bowel Disease, Diagnostic and Therapeutic Strategies -
“Mechanistic Basis of Treatment.” Moscow, Russia. June 9-11, 2006.
Post-Digestive Diseases Week Meeting (2006) - “Controversies in IBD.” Dana Point, CA. July
21-23, 2006.
Grand Rounds at Duke University Hospital Medicine - “The Changing Faces of IBD 2006:
Merging Basic & Clinical Science.” Chapel Hill, N.C. July 28, 2006.
Trends in IBD Therapy 2006 Latest Developments New Implications - “ New Biologicals in the
pipeline.” Huntington Beach, CA. September 7-9, 2006.
7th Annual Update in Gastroenterology - “Advances in the Understanding of IBD
Pathophysiology: The Year in Review” & “Infliximab or Cyclosporin in Severe UC: Case
Studies.” Napa, CA. September 15-17, 2006.
Cleveland Clinic Foundation presented at the IBD Summit- Inflammatory Bowel Disease: Ideas
for the Future- “The Immune Response in IBD: Are We Finding The Mechanisms or The
Therapeutic Targets?” Cleveland, Ohio. October 4-7, 2006.
Congress of the European Crohn’s and Colitis Organization (ECCO) - “Who gets inflammatory
bowel disease?” Innsbruck, Austria. March 1-3, 2007
Targan, Stephan R.
July 9, 2007
Page 12
Genentech - “The ever changing faces of IBD: Implications for drug developement.” San
Francisco, CA . March 16, 2007.
Visiting Professor at UCLA - “TL1A (TNFSFIS) and Mucosal Immunobiology - Man to Mouse
and Back to Man” and “IBD 2007: A Model Disease For Merging Basic, Translational and
Clinical Science.” Los Angeles, CA. March 20-21, 2007.
Penn IBD Symposium - “The role of the adaptive immune system in IBD pathology and
therapies” and “Can we predict the disease course for patients with IBD?” Philadelphia, PA.
March 23-24, 2007.
DDW Liver & Gut Club, The Liver Institute Methodist Hospital- "Changing Faces of IBD:
Importance for Novel Drug Discovery". Dallas, Texas. March 26, 2007.
Grand Rounds at Methodist Hospital - "Changing Faces of IBD: Merging Basic Translational &
Clinical Science". Dallas, Texas. March 27, 2007.
Grand Rounds at University of New Mexico - “TL1A (TNFSFIS) and Mucosal Immunobiology -
Man to Mouse and Back to Man”. Albuquerque, New Mexico. April 26, 2007.
7th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) - “IBD 2007:
A Model Disease for Merging Basic, Translational and Clinical Science”. San Diego, CA. June
7-11, 2007.
PUBLICATIONS/BIBLIOGRAPHIES:
A. Research Papers - Peer-Reviewed
1. Targan SR, Merrill S, Schwabe AD. Fractionation and quantification of beta carotene and
vitamin A derivatives in human serum. Clin Chem 1969;15:479-86.
2. Targan SR, Chassin MR, Guze LB. Dilantin-induced disseminated intravascular
coagulation with purpura fulminans. A case report. Ann Intern Med 1975;83:227-30.
3. Chow AW, Soll BA, Targan SR, Buze LB. Hyperamylasemia associated with gonococcal
salpingitis and perihepatitis. Obstet Gynecol 1976;48:29S-30S.
4. Bayer AS, Targan SR, Pitchon HE, Guze LB. Dilantin toxicity: miliary pulmonary
infiltrates and hypoxemia. Ann Intern Med 1976;85:475-6.
5. Targan SR, Chow AW, Guze LB. Spontaneous peritonitis of cirrhosis due to
Campylobacter fetus. Gastroenterology 1976;71(2):311-13.
6. Targan SR, Chow AW, Guze LB. Campylobacter fetus associated with pulmonary
abscess and empyema. Chest 1977;71:105-8.
7. Targan SR, Chow AW, Guze LB. Role of anaerobic bacteria in spontaneous peritonitis of
cirrhosis: report of two cases and review of the literature. Am J Med 1977;62:397-403.
8. Jondal M, Targan S. In vitro induction of cytotoxic effector cells with spontaneous killer
cell specificity. J Exp Med 1978;147:1621-36.
9. Targan S, Jondal M. Monolayer immune complex (MIC) fractionation of Fc receptor
bearing human spontaneous killer cells. J Immunol Methods 1978;22:123-9.
10. Jondal M, Spine C, Targan S. Human spontaneous killer cells selective for tumourderived
target cells. Nature 1978;272:62-4.
Targan, Stephan R.
July 9, 2007
Page 13
11. Jondal M, Targan S. Spontaneous and lectin-dependent cellular cytotoxicity by
lymphocyte subpopulations against cell lines susceptible or resistant to spontaneous
cytotoxicity. Clin Exp Immunol 1978;33:121-7.
12. Targan S, Jondal M. Lack of Fc receptor expression on cytotoxic effector cells with
spontaneous killer (SK) cell specificity induced by stimulation with B cell lines. J Clin
Lab Immunol 1979;1:343-50.
13. Targan S, Dorey F. Dual mechanism of interferon augmentation of natural killer
cytotoxicity (NKCC). Ann N Y Acad Sci 1980;350:121-9.
14. Targan SR, Gale RP, Jondal M. Bone marrow modulation of spontaneous killer cellular
cytotoxicity (SKCC) induction. J Clin Lab Immunol 1980;4:1-6.
15. Targan S, Dorey F. Interferon activation of "pre-spontaneous killer" (pre-SK) cells and
alteration in kinetics of lysis of both "pre-SK" and active SK cells. J Immunol
1980;124:2157-61.
16. Silva A, Bonavida B, Targan S. Mode of action of interferon-mediated modulation of
natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of
lysis. J Immunol 1980;125:479-84.
17. Kendall RA, Targan S. The dual effect of prostaglandin (PGE2) and ethanol on the
natural killer cytolytic process: effector activation and NK-cell-target cell conjugate lytic
inhibition. J Immunol 1980;125:2770-7.
18. Targan S, Grimm E, Bonavida B. A single cell marker of active NK cytotoxicity: only a
fraction of target binding lymphocytes are killer cells. J Clin Lab Immunol 1980;4:165-8.
19. Targan SR. The dual interaction of prostaglandin E2 (PGE2) and interferon (IFN) on NK
lytic activation: enhanced capacity of effector-target lytic interactions (recycling) and
blockage of pre-NK cell recruitment. J Immunol 1981;127:1424-8.
20. Targan S, Britvan L, Dorey F. Activation of human NKCC by moderate exercise:
increased frequency of NK cells with enhanced capability of effector--target lytic
interactions. Clin Exp Immunol 1981;45:352-60.
21. Targan S, Stebbing N. In vitro interactions of purified cloned human interferons on NK
cells: enhanced activation. J Immunol 1982;129:934-5.
22. Hiserodt JC, Britvan LJ, Targan SR. Differential effects of various pharmacological
agents on the cytolytic reaction mechanism of the human natural killer lymphocyte:
further resolution of programming for lysis and KCIL into discrete stages. J Immunol
1982;129:2266-70.
23. Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation
of ulcerative colitis. N Engl J Med 1982;306:409-12.
24. Targan SR. Understanding the NK cytolytic process by studying mechanisms of
activation. Adv Exp Med Biol 1982;146:389-402.
25. Hiserodt JC, Britvan LJ, Targan SR. Inhibition of human natural killing by heterologous
and monoclonal antibodies. J Immunol 1982;129:2248-54.
26. Hiserodt JC, Britvan LJ, Targan SR. Characterization of the cytolytic reaction mechanism
of the human natural killer (NK) lymphocyte: resolution into binding, programming, and
killer cell-independent steps. J Immunol 1982;129:1782-7.
27. Targan SR, Newman W. Definition of a "trigger" stage in the NK cytolytic reaction
sequence by a monoclonal antibody to the glycoprotein T-200. J Immunol
1983;131:1149-53.
Targan, Stephan R.
July 9, 2007
Page 14
28. Hiserodt JC, Britvan LJ, Targan SR. Studies on the mechanism of the human natural
killer cell lethal hit: evidence for transfer of protease-sensitive structures requisite for
target cell lysis. J Immunol 1983;131:2710-3.
29. Targan SR, Oseas R. The "lazy" NK cells of Chediak-Higashi syndrome. J Immunol
1983;130:2671-4.
30. Targan S, Decker JM, Ades EW. Mechanism of inhibition of natural killing by a
glycopeptide isolated from the K562 plasma membrane. Nat Immun Cell Growth Regul
1983;3:113-23.
31. Targan SR, Britvan L, Kendal R, Vimadalal S, Soll A. Isolation of spontaneous and
interferon inducible natural killer like cells from human colonic mucosa: lysis of
lymphoid and autologous epithelial target cells. Clin Exp Immunol 1983;54:14-22.
32. Hiserodt JC, Britvan L, Targan SR. Studies on the mechanism of the human natural killer
cell lethal hit: analysis of the mechanism of protease inhibition of the lethal hit. J
Immunol 1983;131:2705-9.
33. Farram E, Targan SR. Identification of human natural killer soluble cytotoxic factors
(NKCF) derived from NK-enriched lymphocyte populations: specificity of generation
and killing. J Immunol 1983;130:1252-6.
34. Newman W, Targan SR, Fast LD. Immunobiological and immunochemical aspects of the
T-200 family of glycoproteins. Mol Immunol 1984;21:1113-21.
35. Deem RL, Targan SR. Evidence of a dynamic role of the target cell membrane during the
early stages of the natural killer cell lethal hit. J Immunol 1984;133:72-7.
36. Brieva JA, Targan SR, Stevens RH. NK and T cell subsets regulate antibody production
by human in vivo antigen-induced lymphoblastoid B cells. J Immunol 1984;132:611-5.
37. Deem RL, Targan SR. Sequential substages of natural killer cell-derived cytolytic factor
(NKCF)-mediated cytolysis as defined by glutaraldehyde modulation of the target cell. J
Immunol 1984;133:1836-40.
38. Hiserodt J, Britvan L, Targan SR. Studies on the mechanism of the human natural killer
cell lethal hit: a new method for rapid physical isolation of lethally hit K562 targets and
inhibition of cytolysis by reduced temperature or trypsin. Cell Immunol 1984;83:43-51.
39. Deem RL, Targan SR. Analysis of sequential substages of the natural killer cell lethal hit.
Adv Exp Med Biol 1985;184:239-56.
40. Stevens R, Oliver M, Brogan M, Heiserodt J, Targan SR. Defective generation of tetanusspecific
antibody-producing B cells after in vivo immunization of Crohn's disease and
ulcerative colitis patients. Gastroenterology 1985;88(6):1860-66.
41. Brogan M, Hiserodt J, Oliver M, Stevens R, Korelitz B, Targan SR. The effect of 6-
mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol
1985;5:204-11.
42. Targan SR, Brieva J, Newman W, Stevens R. Is the NK lytic process involved in the
mechanism of NK suppression of antibody-producing cells? J Immunol 1985;134:666-9.
43. Guze PA, Karavodin LM, Bonavida B, Kalmanson GM, Ishida K, Targan SR, Guze LB.
Strain-dependent differences in susceptibility of mice to experimental pyelonephritis. J
Infect Dis 1985;152:416-9.
44. Elson CO, Kagnoff MF, Fiocchi C, Befus AD, Targan SR. Intestinal immunity and
inflammation: recent progress. Gastroenterology 1986;91(3):746-68.
Targan, Stephan R.
July 9, 2007
Page 15
45. Deem RL, Niederlehner A, Targan SR. Active target cell processes, possibly involving
receptor-mediated endocytosis, are critical for expression of cytotoxicity by natural killer
cell-derived cytolytic factor. Cell Immunol 1986;102:187-97.
46. Shanahan F, Brogan MD, Newman W, Targan SR. K562 killing by K, IL 2-responsive
NK, and T cells involves different effector cell post-binding trigger mechanisms. J
Immunol 1986;137:723-6.
47. Shanahan F, Niederlehner A, MacDermott RP, Stenson WF, Kane MG, Targan SR.
Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit
different stages of the NK and NKCF lytic processes. Immunopharmacology
1986;11:111-8.
48. Brogan M, Targan SR. Evidence for involvement of serine proteases in the late stages of
the natural killer cell lytic reaction. Cell Immunol 1986;103:426-33.
49. Kimata H, Shanahan F, Brogan M, Targan SR, Saxon A. Modulation of ongoing human
immunoglobulin synthesis by natural killer cells. Cell Immunol 1987;107:74-88.
50. Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell
formation in patients with inflammatory bowel disease following tetanus toxoid booster
immunization. J Clin Lab Immunol 1987;24:69-74.
51. Shanahan F, Brogan M, Targan SR. Human mucosal cytotoxic effector cells.
Gastroenterology 1987;92(6):1951-57.
52. Shanahan F, Targan SR. Sulfasalazine and salicylate-induced exacerbation of ulcerative
colitis. N Engl J Med 1987;317:455.
53. Targan SR, Kagnoff MF, Brogan MD, Shanahan F. Immunologic mechanisms in
intestinal diseases. Ann Intern Med 1987;106:853-70.
54. Shanahan F, Brogan M, Nayersina R, Targan SR. Cytotoxic lymphocytes in human
intestinal mucosa. Adv Exp Med Biol 1987;216A:457-63.
55. Deem RL, Britvan LJ, Targan SR. Definition of a secondary target cell trigger during
natural killer cell cytotoxicity: possible role of phospholipase A2. Cell Immunol
1987;110:253-64.
56. Karp LC, Targan SR. New enema treatments for inflammatory bowel disease. Dig Dis
Sci 1988;33:85S-87S.
57. Anton PA, Targan SR, Vigna SR, Durham M, Schwabe AD, Shanahan F. Enhanced
neutrophil chemiluminescence in familial Mediterranean fever. J Clin Immunol
1988;8:148-56.
58. Deem RL, Shanahan F, Niederlehner A, Targan SR. Role of the CD45 (T-200) molecule
in anti-CD3-triggered T cell-mediated cytotoxicity. Cell Immunol 1988;117:99-110.
59. Shanahan F, Deem R, Nayersina R, Leman B, Targan SR. Human mucosal T-cell
cytotoxicity. Gastroenterology 1988;94(4):960-7.
60. Shanahan F, Randolph L, King R, Oseas R, Brogan M, Witkop C, Rotter J, Targan SR.
Hermansky-Pudlak syndrome: an immunologic assessment of 15 cases. Am J Med
1988;85:823-8.
61. Vidrich A, Ravindranath R, Farsi K, Targan SR. A method for the rapid establishment of
normal adult mammalian colonic epithelial cell cultures. In Vitro Cell Dev Biol
1988;24:188-94.
Targan, Stephan R.
July 9, 2007
Page 16
62. Shanahan F, Leman B, Deem R, Niederlehner A, Brogan M, Targan SR. Enhanced
peripheral blood T-cell cytotoxicity in inflammatory bowel disease. J Clin Immunol
1989;9:55-64.
63. Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the
proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's
disease. Gastroenterology 1989;97(1):20-28.
64. Randolph LM, Toyoda H, McElree CK, Shanahan F, Targan SR, Rotter JI. Lack of an
association between polymorphisms of the T-cell receptor alpha-chain and ulcerative
colitis. Gastroenterology 1989;97(5):1115-20.
65. Deem RL, Targan SR, Niederlehner A, Shanahan F. The CD8+ Leu-7+ subset of T cells
in Crohn's disease: distinction between cytotoxic and covert suppressor functions. Clin
Exp Immunol 1990;80:387-94.
66. Saxon A, Shanahan F, Landers C, Ganz T, Targan SR. A distinct subset of antineutrophil
cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin
Immunol 1990;86:202-10.
67. Duerr RH, Targan SR, Landers CJ, LaRusso NF, Lindsay KL, Wiesner RH, Shanahan F.
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and
ulcerative colitis. Gastroenterology 1991;100(5):1385-91.
68. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil
cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal
illnesses. Gastroenterology 1991;100(6):1590-96.
69. Deem RL, Shanahan F, Targan SR. Triggered human mucosal T cells release tumour
necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells.
Clin Exp Immunol 1991;83:79-84.
70. Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo
SK, Targan SR, Cerda JJ, et al. Oral mesalamine (Asacol) for mildly to moderately active
ulcerative colitis. A multicenter study. Ann Intern Med 1991;115:350-5.
71. Shanahan F, Landers C, Duerr R, Targan SR. Neutrophil autoantibodies as disease
markers for ulcerative colitis. Immunol Res 1991;10:479-84.
72. Shanahan F, Targan SR, Anton P, Duerr R. Colonoscopy during an attack of severe
ulcerative colitis. Am J Gastroenterol 1991;86:1278.
73. Targan SR, Deem RL, Shanahan F. Role of mucosal T-cell-generated cytokines in
epithelial cell injury. Immunol Res 1991;10:472-8.
74. Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C, Landers CJ,
Targan SR. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and
genetic heterogeneity. Gastroenterology 1992;103(2):456-61.
75. Targan SR, Landers CJ, King NW, Podolsky DJ, Shanahan F. Ulcerative colitis-linked
antineutrophil cytoplasmic antibody in the cotton-top tamarin model of colitis.
Gastroenterology 1992;102(5):1493-98.
76. Miner PB, Jr., Peppercorn MA, Targan SR. A rational approach to 5-aminosalicylic acid
therapy in ulcerative colitis. Hosp Pract (Off Ed) 1993;28:1-24.
77. Andus T, Targan SR, Deem R, Toyoda H. Measurement of tumor necrosis factor alpha
mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg
Immunol 1993;5:11-7.
Targan, Stephan R.
July 9, 2007
Page 17
78. Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, Targan SR. Ulcerative
colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and
subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993;92:1080-
4.
79. Toyoda H, Wang SJ, Yang HY, Redford A, Magalong D, Tyan D, McElree CK,
Pressman SR, Shanahan F, Targan SR, Rotter JI. Distinct associations of HLA class II
genes with inflammatory bowel disease. Gastroenterology 1993;104:741-48.
80. Treem WR, Veligati LN, Rotter JI, Targan SR, Hyams JS. Ulcerative colitis and total
alopecia in a mother and her son. Gastroenterology 1993;104(4):1187-91.
81. Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical
risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut
1993;34:517-24.
82. Berberian LS, Valles-Ayoub Y, Gordon LK, Targan SR, Braun J. Expression of a novel
autoantibody defined by the VH3-15 gene in inflammatory bowel disease and
Campylobacter jejuni enterocolitis. J Immunol 1994;153:3756-63.
83. Gilbert RS, Reddy ST, Targan SR, Herschman HR. TGF-beta 1 augments expression of
the TIS10/prostaglandin synthase-2 gene in intestinal epithelial cells. Cell Mol Biol Res
1994;40:653-60.
84. Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR. Anti-neutrophil
cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994;125:707-11.
85. Targan SR, Deem RL, Liu M, Wang S, Nel A. Definition of a lamina propria T cell
responsive state. Enhanced cytokine responsiveness of T cells stimulated through the
CD2 pathway. J Immunol 1995;154:664-75.
86. Kim WH, Choi PM, Landers CJ, Targan SR. Role of antineutrophil cytoplasmic
antibodies in an ethnically distinct population: Korean patients with ulcerative colitis. Am
J Gastroenterol 1995;90:1953-8.
87. Billing P, Tahir S, Calfin B, Gagne G, Cobb L, Targan SR, Vidrich A. Nuclear
localization of the antigen detected by ulcerative colitis-associated perinuclear
antineutrophil cytoplasmic antibodies. Am J Pathol 1995;147:979-87.
88. Yang H, Vora DK, Targan SR, Toyoda H, Beaudet AL, Rotter JI. Intercellular adhesion
molecule 1 gene associations with immunologic subsets of inflammatory bowel disease.
Gastroenterology 1995;109(2):440-48.
89. Zins BJ, Sandborn WJ, Penna CR, Landers CJ, Targan SR, Tremaine WJ, Wiesner RH,
Dozois RR. Pouchitis disease course after orthotopic liver transplantation in patients with
primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol
1995;90:2177-81.
90. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic
antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J
Gastroenterol 1995;90:740-7.
91. Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of
subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin.
Dis Colon Rectum 1995;38:1241-5.
92. Vidrich A, Lee J, James E, Cobb L, Targan SR. Segregation of pANCA antigenic
recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune
hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;15:293-9.
Targan, Stephan R.
July 9, 2007
Page 18
93. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic
antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;108(4):1159-66.
94. Targan SR, Landers CJ, Cobb L, MacDermott RP, Vidrich A. Perinuclear anti-neutrophil
cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative
colitis patients. J Immunol 1995;155:3262-7.
95. Abreu-Martin MT, Vidrich A, Lynch DH, Targan SR. Divergent induction of apoptosis
and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J
Immunol 1995;155:4147-54.
96. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil
cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results
of a pilot study. Mayo Clin Proc 1996;71(5):431-6.
97. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, Rotter JI,
Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies in patients with
Crohn's disease define a clinical subgroup. Gastroenterology 1996;110(6):1810-19.
98. Plevy SE, Targan SR, Yang H, Fernandez D, Rotter JI, Toyoda H. Tumor necrosis factor
microsatellites define a Crohn's disease-associated haplotype on chromosome 6.
Gastroenterology 1996;110(4):1053-60.
99. Eggena M, Targan SR, Iwanczyk L, Vidrich A, Gordon LK, Braun J. Phage display
cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil
cytoplasmic antibody) in ulcerative colitis. J Immunol 1996;156(10):4005-11.
100. Ohmen JD, Yang HY, Yamamoto KK, Zhao HY, Ma Y, Bentley LG, Huang Z, Gerwehr
S, Pressman S, McElree C, Targan SR, Rotter JI, Fischel-Ghodsian N. Susceptibility
locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease,
but not in ulcerative colitis. Hum Mol Genet 1996;5(10):1679-83.
101. Aranda R, Sydora BC, McAllister PL, Binder SW, Yang HY, Targan SR, Kronenberg M.
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+,
CD45RBhigh T cells to SCID recipients. J Immunol 1997;158(7):3464-73.
102. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T,
Targan SR, Fleishman C, Wiita B. A double-blind comparison of oral versus rectal
mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J
Gastroenterol 1997;92(10):1867-71.
103. Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan SR, Landers C,
Jewell DP. Genetic markers may predict disease behavior in patients with ulcerative
colitis. Gastroenterology 1997;112(6):1845-53.
104. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. A
role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's
disease. J Immunol 1997;159(12):6276-82.
105. Compton RF, Sandborn WJ, Yang H, Lindor NM, Tremaine WJ, Davis MD, Khalil AA,
Tountas NA, Tyan DB, Landers CJ, Taylor KD, Viggiano TR, Matteson EL, Schroeter
AL, Plevy SE, Cominelli F, Targan SR, Rotter JI. A new syndrome of Crohn's disease
and pachydermoperiostosis in a family. Gastroenterology 1997;112(1):241-49.
106. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody
KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2
to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N
Engl J Med 1997;337(15):1029-35.
Targan, Stephan R.
July 9, 2007
Page 19
107. Kaditis AG, Perrault J, Sandborn WJ, Landers CJ, Zinsmeister AR, Targan SR.
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal
pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr
1998;26(4):386-92.
108. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan SR, Jewell DP. The presence of antineutrophil
antibodies reflects clinical and genetic heterogeneity within inflammatory
bowel disease. Inflamm Bowel Dis 1998(1);4:18-26.
109. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic
accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology
1998;115(4):822-9.
110. Gonsky R, Deem RL, Hughes CC, Targan SR. Activation of the CD2 pathway in lamina
propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter,
resulting in messenger RNA transcription and IL-2 secretion. J Immunol
1998;160(10):4914-22.
111. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G,
Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies
combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease:
prevalence and diagnostic role. Gut 1998;42(6):788-91.
112. Ma Y, Ohmen JD, Li Z, Bentley LG, McElree C, Pressman S, Targan SR, Fischel-
Ghodsian N, Rotter JI, Yang H. A genome-wide search identifies potential new
susceptibility loci for Crohn's disease. Inflamm Bowel Dis 1999;5:271-8.
113. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer
SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ,
Gordon S, Kleoudis CS, Murdock RH, Jr. Lack of effect of intravenous administration on
time to respond to azathioprine for steroid-treated Crohn's disease. North American
Azathioprine Study Group. Gastroenterology 1999;117:527-35.
114. Gordon LK, Eggena M, Targan SR, Braun J. Definition of ocular antigens in ciliary body
and retinal ganglion cells by the marker antibody pANCA. Invest Ophthalmol Vis Sci
1999;40(6):1250-5.
115. Rutgeerts P, D'Haens G, Targan SR, Vasiliauskas E, Hanauer SB, Present DH, Mayer L,
Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy
and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to
maintain remission in Crohn's disease. Gastroenterology 1999 Oct;117(4):761-69.
116. Rutgeerts PJ, Targan SR. Introduction: anti-TNF strategies in the treatment of Crohn's
disease. Aliment Pharmacol Ther 1999;13(4):1.
117. Gonsky R, Deem RL, Lee DH, Chen A, Targan SR. CD28 costimulation augments IL-2
secretion of activated lamina propria T cells by increasing mRNA stability without
enhancing IL-2 gene transactivation. J Immunol 1999 Jun;162(11):6621-9.
118. Yang H, Plevy SE, Taylor K, Tyan D, Fischel-Ghodsian N, McElree C, Targan SR,
Rotter JI. Linkage of Crohn's disease to the major histocompatibility complex region is
detected by multiple non-parametric analyses. Gut 1999;44(4):519-26.
119. Yang H, Ohmen JD, Ma Y, Targan SR, Fischel-Ghodsian N, Rotter JI. Additional
evidence of linkage between Crohn's disease and a putative locus on chromosome 12.
Genet Med 1999;1(5):194-8.
Targan, Stephan R.
July 9, 2007
Page 20
120. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky
DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab
for the treatment of fistulas in patients with Crohn's disease. N Engl J Med
1999;340(18):1398-405.
121. Prehn JL, Landers CJ, Targan SR. A soluble factor produced by lamina propria
mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by
T cells. J Immunol 1999 Oct;163(8):4277-83.
122. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H,
Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically
active, steroid-dependent Crohn's disease. Gastroenterology 1999;117(6):1278-87.
123. Facklis K, Plevy SE, Vasiliauskas EA, Kam L, Taylor K, Targan SR, Fleshner PR.
Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative
colitis patients and may be associated with pouch-specific complications. Dis Colon
Rectum 1999 May ;42(5):601-5; discussion 605-6.
124. Cohavy O, Harth G, Horwitz M, Eggena M, Landers C, Sutton C, Targan SR, Braun J.
Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic
target of pANCA monoclonal antibody and serum immunoglobulin A from patients with
Crohn's disease. Infect Immun 1999;67:6510-7.
125. Abreu-Martin MT, Palladino AA, Faris M, Carramanzana NM, Nel AE, Targan SR. Fas
activates the JNK pathway in human colonic epithelial cells: lack of a direct role in
apoptosis. Am J Physiol 1999;276:G599-605.
126. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG.
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in
inflammatory bowel disease. Gastroenterology 2000;118(4):705-13.
127. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-
Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of
patients with Crohn's disease. Gut 2000 Jan;46(1):58-63.
128. Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, Braun J.
Identification of a novel bacterial sequence associated with Crohn's disease.
Gastroenterology July 2000; 119(1):23-31.
129. Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Efficacy of
mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for
Crohn's disease. Inflamm Bowel Dis 2000;6:16-20.
130. Gordon LK, Eggena M, Targan SR, Braun J. Mast cell and neuroendocrine cytoplasmic
autoantigen(s) detected by monoclonal pANCA antibodies. Clin Immunol 2000;94(1):42-
50.
131. Gonsky R, Deem RL, Bream JH, Lee DH, Young HA, Targan SR. Mucosa-specific
targets for regulation of IFN-gamma expression: lamina propria T cells use different ciselements
than peripheral blood T cells to regulate transactivation of IFN-gamma
expression. J Immunol 2000 Feb;164(3):1399-407.
132. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors
predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative
colitis. Am J Gastroenterol 2000;95(8):2000-8.
Targan, Stephan R.
July 9, 2007
Page 21
133. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody
expression stratifies Crohn's disease into immunologically homogeneous subgroups with
distinct clinical characteristics. Gut 2000;47(4):487-96.
134. Trachtenberg EA, Yang H, Hayes E, Vinson M, Lin C, Targan SR, Tyan D, Erlich H,
Rotter JI. HLA class II haplotype associations with inflammatory bowel disease in Jewish
(Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 2000;61(3):326-33.
135. Pimentel M, Chang M, Chow EJ, Tabibzadeh S, Kirit-Kiriak V, Targan SR, Lin HC.
Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
Am J Gastroenterol 2000 Dec; 95(12):3458-62.
136. Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J.
Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect
Immun 2000;68(3):1542-8.
137. Targan SR. Biology of inflammation in Crohn's disease: mechanisms of action of anti-
TNF-a therapy. Can J Gastroenterol 2000 Sept;14:13C-16C.
138. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD, Andrew DP, Targan
SR. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in
the regional specialization of the mucosal immune system. J Immunol 2000
Nov;165(9):5069-76.
139. Eggena M, Cohavy O, Parseghian MH, Hamkalo BA, Clemens D, Targan SR, Gordon
LK, Braun J. Identification of histone H1 as a cognate antigen of the ulcerative colitisassociated
marker antibody pANCA. J Autoimmun 2000 Feb;14(1):83-97.
140. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of
serodiagnostic testing in suspected pediatric inflammatory bowel disease.
Am J Gastroenterol 2001;96(3):758-65.
141. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR,
Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a
pilot study. Inflamm Bowel Dis 2001 May;7(2):83-8.
142. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf
DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan
SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a
randomized double-blind placebo-controlled trial. Gastroenterology 2001
May;120(6):1330-38.
143. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C,
Schaible T, Plevy SE, Targan SR, Rutgeerts P. Infliximab induces potent antiinflammatory
and local immunomodulatory activity but no systemic immune suppression
in patients with Crohn's disease. Aliment Pharmacol Ther 2001;15(4):463-73.
144. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA
pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody
treatment in Crohn's disease. Gastroenterology 2001;120(6):1347-55.
145. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA.
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.
Am J Gastroenterol 2001 Jul;96(7):2137-42.
146. Prehn JL, Landers C, Muller GW, Man HW, Stirling DI, Targan SR. Potent inhibition of
cytokine production from intestinal lamina propria T cells by phosphodiesterase-4
inhibitory thalidomide analogues. J of Clin Immunology 2001 Sept; 21(5):357-64.
Targan, Stephan R.
July 9, 2007
Page 22
147. Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, Deem R, Breaverman T,
Ponath PD, Andrew DP, Green PHR, Hodge MR, Binder SW, Targan SR. CCR9-
positive lymphocytes and thymus-expressed chemokine distinguish small bowel from
colonic Crohn’s disease. Gastroenterology 2001 Aug;121(2):246-54.
148. Sandborn WJ, Loftus EV, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid
B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR,
Targan SR. Evaluation of serologic disease markers in a population based cohort of
patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2001 Aug;
7(3):192-201.
149. Dubinsky MC, Hassard PV, Kam KY Abreu MT, Seidman EG, Targan SR, Vasiliauskas
EA. An open-label pilot study using thioguanine as a therapeutic alternative in a
subgroup of inflammatory bowel disease patients resistant to 6-mercaptopurine therapy.
Inflamm Bowel Dis 2001 Aug; 7(3):181-89.
150. Wei B, Dalwadi H, Gordon LK, Landers C, Targan SR, Braun J. Molecular cloning of a
Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory
bowel disease marker antibody. Infect and Immun 2001 Oct; 69(10):6044-54.
151. Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner N, Gaiennie J. Abreu-Martin MT,
Targan SR. High-level perinuclear ANCA in ulcerative colitis patients before colectomy
predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut
2001 Nov; 49(5):671-77.
152. Dubinsky MC, Yang HY, Hassard PV, Seidman EG, Kam LY, Abreu, MT, Targan SR,
Vasiliauskas, EA. Preliminary evidence suggests that 6-MP metabolite profiles provide a
biochemical explanation for 6-MP resistance in patients with inflammatory bowel
disease. Gastroenterology 2002 122(4):1165-67;11910368.
153. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR,
Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP
resistance in patients with inflammatory bowel disease. Gastroenterology Apr 2002
122(4): 904-915.
154. Abreu MT, Taylor KD, Lin Y, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam
LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are
associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology
Sept 2002;123(3):679-688.
155. Landers CJ, Cohavy O, Misra R, Yang H, Lin Y, Braun J, Targan SR. Selected loss of
tolerance evidenced by Crohn’s disease-associated immune responses to auto and
individual bacterial antigens. Gastroenterology Sep 2002;123(3):689-699.
156. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P,
Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine (6-TG) Can Cause
Serious Liver Injury in Inflammatory Bowel Disease (IBD) Patients. Gastroenterology
2003; 125(2): 298-303.
157. Sugimura K, Taylor KD, Lin Y-C, Hang T, Wang D, Tang Y-M, Ghodsian NF, Targan
SR, Rotter JI, Yang H. A novel NOD2/CARD15 haplotype conferring risk for Crohn’s
disease in Ashkenazi Jews. American Journal of Human Genetics Mar 2003; 72 (3):509-
518.
158. Papadakis KA, Rosenbloom B, Targan SR. Anti-CD20 chimeric monoclonal antibody
(rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn’s
disease. Gastroenterology Feb 2003; 124(2): 583.
159. Gonsky R, Deem RL, Young HA, Targan SR. CD2 mediates activation of the IFNgamma
intronic STAT binding region in mucosal T cells. European J Immunol. May
2003;33(5):1152-62.
160. Elson CO, Sartor RB, Targan SR, Sandborn WJ. Challenges in IBD Research: updating
the scientific agendas. IBD Journal May 2004; 9(3):137-53.
Targan, Stephan R.
July 9, 2007
Page 23
161. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR. Targan SR, Vasiliauskas EA.
Infliximab in the treatment of medically refractory indeterminate colitis. Alimentary
Pharmacology and Therapeutics 2003; 18 (7):741-747.
162. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas, EA. Thioguanine (6-
TG): A potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or
azathioprine. American Journal of Gastroenterology May 2003; 98(5): 1058-63.
163. Papadakis KA, Landers C, Prehn j, Kouroumalis EA, Moreno ST, Hodge MR, Targan
SR. CC chemokine receptor 9 expression defines a subset of peripheral blood
lymphocytes with mucosal T-cell phenotype and T helper 1 (Th1) or T regulatory 1 (Tr1)
cytokine profile. Journal of Immunology July 2003;171(1): 159-65.
164. Mow WS, Lo SK, Targan SR, Dubinsky MC, Treyzon L, Abreu MT, Papadakis KA,
Vasiliauskas EA. Initial experience with wireless capsule enteroscopy in the diagnosis
and management of inflammatory bowel disease. Clinical Gastroenterology and
Hepatology, January 2004; (1): 31-40.
165. Mow WS, Abreu MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High
incidence of anergy in inflammatory bowel disease patients limits the usefulness of
tuberculin skin testing prior to infliximab therapy. Clinical Gastroenterology and
Hepatology. January 2004; 2(4): 309-13.
166. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers
CJ, Abreu-Martin MT, Rotter JL, Yang H, Targan SR. Association of antibody responses
to microbial antigens and complications of small bowel Crohn’s disease.
Gastroenterology 2004; 126(2): 414-24.
167. Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T,
Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and
submicroscopic fibrosis associated with 6-thioguanine (6-TG) therapy in inflammatory
bowel disease (IBD). The American Journal of Surgical Pathology 2004; 28:1204-1211.
168. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg
RM. Bacterial flagellin is a dominant antigen in Crohn’s disease. Journal of Clinical
Investigation 2004;113(9): 1296-1306.
169. Papadakis KA, Prehn JL, Landers C, Han Q, Lou X, Cha SC, Wei P, Targan SR. TL1A
synergizes with IL-12/IL-18 to enhanced IFN-gamma production in human T and NK
cells. J Immunol 2004 Jun 1;172(11):7002-7.
170. Cohavy O, Zhou J, Granger SW, Ware CF, Targan SR. LIGHT expression by mucosal T
cells may regulate IFN-γ expression in the intestine. J Immunol. 2004 Jul 1;173(1):251-8.
171. Sandborn W, C
|